Androgenitic alopecia.
Conditions
Interventions
Intervention 1: Intervention group: patients prescribed oral dutasteride 0.5 mg per day for 6 months. Intervention 2: Control group: patients prescribed oral spironolactone 100 mg per day for 6 months
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ?Androgenitic alopecia female patients
Exclusion criteria
Exclusion criteria: History of breast cancer Usage of another AGA treatment in the past 3 months Pregnancy or a plan to get ptegnant in the next year Smoking or alchohol addiction Drug reaction to dutasteride or spironolactone History of hair transplant History of any dermatologic or systemic disease that affect hair
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair density increase in the vertex area. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Trichoscopy report.;Hair thickness increase. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Tricoscopy report. | — |
Secondary
| Measure | Time frame |
|---|---|
| Alopecia grade. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Sinclair scale.;Treatment response. Timepoint: 3 months after treatment , 6 months after treament. Method of measurement: Questionnaire.;Patient quality of life. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Dermatology life Quality Index questionnaire.;Drug complications. Timepoint: 1 month after treatment, 3 months after treatment , 6 months after treament. Method of measurement: Questionnaire.;Villus and terminal hair number. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Trichoscopy report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ifa Etesami
Tehran University of Medical Sciences
Outcome results
None listed